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Abstract
Introduction The majority of individuals who suffer an
episode of depression go on to experience recurrences. We
have proposed, based upon the observation that reducing
serotonin via acute tryptophan depletion (ATD) is more
likely to induce negative mood in recovered depressed
individuals than never depressed individuals, that this may
be because associations form between negative mood and
reduced serotoninduring an episodeof depression (Robinson
and Sahakian, Psychol Med 38:315–318, 2008b). Such
associations would mean that subsequent reductions in
serotonin are more likely to provoke depressed mood and
hence trigger an episode of depression.
Methods In this study, we tested this hypothesis by
manipulating the mood state of healthy females undergoing
ATD (or balanced placebo) on two separate testing sessions.
On the first session, subjects received either negative or
neutral mood induction, while on the second session all
subjects received neutral mood induction.
Results Our findings demonstrate significant ATD-induced
negative mood exclusively on the second visit of subjects
who received both ATD and negative mood induction
procedure on their first visit.
Discussion These findings may be explained by the
formation of an association between the negative mood
and reduced serotonin states during the first visit. As such,
these findings provide preliminary support for the associa-
tive hypothesis of recurrence in depression.
Conclusion Such associations might therefore explain the
discrepancy between the effects of ATD in recovered- and
never-depressed individuals and may, in turn, explain why
an episode of depression increases the risk of subsequent
episodes.
Keywords Serotonin.Mood.Females.Recurrence.
Depression.Associativelearning
Introduction
Depressive disorders are amongst the leading causes of
disability and mortality worldwide and account for more
years lived with disease than any other illness (Beddington
et al. 2008; Murray and Lopez 1996). Furthermore, the
majority of depressed individuals relapse (Mueller et al.
1999), and with each successive episode, the rate of
subsequent recurrence increases (Kessing et al. 2004)s u c h
that life for most sufferers becomes a chronic cycle of illness
and recovery.
The monoamine serotonin (5-HT) is thought to play a
role in major depression (Owens and Nemeroff 1994, but
see Lacasse and Leo 2005 for an alternative view).
Specifically, patients with depression show reduced seroto-
nin levels (Cowen et al. 1989; Placidi et al. 2001),
abnormal serotonin receptor function (Drevets et al. 1999;
Ellis and Salmond 1994) and abnormal serotonin transporter
function (Caspi et al. 2003; Heils et al. 1996; Lesch et al.
1996). Moreover, elevation of serotonin via selective
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One way to manipulate serotonin in healthy individuals
is via the dietary manipulation of the serotonin precursor
tryptophan (acute tryptophan depletion; ATD). This manip-
ulation is thought to significantly reduce central 5-HT
levels (Ardis et al. 2009; Reilly et al. 1997) and can
provoke some of the cognitive effects seen in depressed
individuals in healthy individuals (e.g. Evers et al. 2006;
Murphy et al. 2002; Sambeth et al. 2007). However, ATD
has no reliable effects upon the mood state of healthy
individuals (Robinson and Sahakian 2009; Ruhe et al.
2007). In individuals who have recovered from depression,
on the other hand, ATD can induce significant negative
mood (Delgado et al. 1990; Smith et al. 1997), particularly
in those who were successfully treated with SSRIs (and
therefore presumably had reduced 5-HT) during their first
episode (Booij et al. 2003; Van der Does 2001). An
important unresolved question, therefore, is why a discrep-
ancy exists between the effects of ATD on mood state in
never- and recovered-depressed individuals.
To explain this phenomenon, we have previously
proposed a hypothetical neurocognitive mechanism by
which mood state and reduced serotonin may become
linked during an episode of depression (Robinson and
Sahakian 2008b). The central tenet of this hypothesis is
that associative learning (Dickinson 1981) causes a link to
be formed between the neural substrates implicated in
negative mood and the neural substrates implicated in
a reduced serotonin state during their depression-linked
co-occurrence. Such an association would mean that
re-evocation of one state would trigger the other. In other
words, a permanent association between negative mood
and a low serotonin in depressed individuals would result
in negative mood following an ATD-induced low seroto-
nin state. Individuals who have never suffered from
depression, on the other hand, are not likely to have
previously experienced concurrent reduced serotonin and
negative mood, will not have such an association and will
not therefore experience ATD evoked negative mood. The
term ‘kindling’ has previously been used to describe the
changes that occur during an episode of depression, which
promote the onset of future episodes (Kendler et al. 2001;
Post and Weiss 1998; Segal et al. 1996). A link between
low serotonin and negative mood may therefore underlie
such a kindling effect.
In order to test this hypothesis, we attempted to
artificially associate negative mood with a reduced a
serotonin state in healthy individuals. Mood state was
manipulated via an established mood induction procedure
(MIP; Robinson et al. 2009; Robinson and Sahakian 2009)
and serotonin was manipulated via ATD. Four separate
groups were tested on two occasions separated by at least a
week. In the main group of interest, subjects received ATD
and negative MIP on their first visit but ATD and neutral
MIP on their second visit. Another group received ATD on
both visits but neutral MIP on both the first and second
visit. Two matched control groups received either neutral or
negative MIP on their first visit but received a balanced
amino-acid drink instead of ATD on both visits. Both
control groups also received neutral MIP on their second
visit. If our hypothesis is correct, then ATD will have no
effect upon mood on the first visit (in all groups) but evoke
negative mood on the second visit of the group who
received both ATD and negative MIP on their first visit.
This study therefore tested the hypothesis that associa-
tions can form between reduced serotonin state and
negative mood.
Methods
Procedures were approved by the Cambridge Research
Ethical Committee (06/Q0108/160) and were in accord
with the Helsinki Declaration of 1975. Depression is more
common in females than males (Kendler et al. 2004), and
previous research has demonstrated that ATD has increased
effects in females relative to males (Ellenbogen et al. 1996;
Robinson et al. 2009; Sambeth et al. 2007) so recruitment
was restricted to females. Forty-two subjects were recruited.
One subject failed to complete either testing session. The
remaining 41 subjects were then divided into four groups:
(1) ATD subjects who underwent neutral MIP on visit 1
(N=11), (2) ATD subjects who underwent negative MIP on
visit 1 (N=10), (3) BAL subjects who underwent neutral
MIP on visit 1 (N=10), (4) BAL subjects who underwent
negative MIP on visit 1 (N=10). All subjects received
neutral MIP on visit 2. Thirty-eight subjects completed a
second session (group 1 N=10; group 2, N=8; group 3
N=10; group 4 N=10; Table 1). All subjects were screened
for psychiatric and neurological disorders, gave written
informed consent and were compensated for participation.
Exclusion criteria were cardiac, hepatic, renal, pulmonary,
neurological, psychiatric or gastrointestinal disorders, drug
use and personal or family history of any depressive
disorder. The mean age of subjects was [years] 28 (SD=6).
Subjects were tested on two sessions, separated by at least
Table 1 Group description
Group Visit 1 Visit 2
1 ATD NEUT MIP ATD NEUT MIP
2 ATD NEG MIP ATD NEUT MIP
3 BAL NEUT MIP BAL NEUT MIP
4 BAL NEG MIP BAL NEUT MIP
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caffeine and food from midnight prior to each session.
Protocol
Subjects arrived at the research centre between 08:30 and
10:30 and consumed the amino-acid mixture. At T0, a blood
sample was taken, and a nutritionally balanced (BAL) or a
tryptophan free (ATD) amino-acid drink was ingested.
Following this, they were allowed to consume water and
were given a low protein snack (an apple) for lunch. After a
resting period of approximately 5 h to ensure stable and low
tryptophan levels (Carpenter et al. 1998), a second blood
sample was taken (T1), and the mood induction procedure
was completed.
Amino-acid mixtures
Amino-acid mixtures (prepared by SHS international;
Liverpool, UK) were identical to previous research (Cools
et al. 2007; Robinson et al. 2009; Robinson and Sahakian
2009; Roiser et al. 2006): L-alanine, 2.9 g; L-arginine, 2.6 g;
L-cystine, 1.4 g; glycine, 1.7 g; L-histidine, 1.7 g; L-
isoleucine, 4.2 g; L-leucine, 7.1 g; L-lysine, 4.7 g; L-
methionine, 1.6 g; L-proline, 6.4 g; L-phenylalanine, 3.0 g;
L-serine, 3.6 g; L-threonine, 3.4 g; L-tyrosine, 3.6 g; L-
valine, 4.7 g; L-tryptophan, 2.1 g—total BAL, 54.7/TRP,
52.6 g. The drinks were prepared by stirring the mixture
into approximately 200 ml tap water with either lemon-lime
or grapefruit flavouring. Subjects reported no side effects
apart from transient nausea following ingestion of the drink.
Blood (venous) samples (10 ml) were taken immediately
before ingestion of the amino-acid drink (T0) and approxi-
mately 5 h after administration (T1) to determine the crucial
TRP/sum of the long neutral amino acids (ΣLNAA) ratio.
Mood induction procedure
The MIP has been comprehensively described elsewhere
(Robinson et al. 2009; Robinson and Sahakian 2009).
Subjects were asked to relate negative or neutral Velten
sentences to situations in their own lives whilst listening to
mood-congruent music. It was programmed in Microsoft
Visual Basic 6 (Microsoft Corporation, Redmond, WA,
USA) and presented on a Paceblade tablet computer (11-in.
monitor). A set of visual analogue scales (VAS) was
administered at T0 (admission), T1 (5 h later pre-MIP) and
T2 (post-MIP) to determine self-reported mood.
Results
Amino-acid mixtures
Incomplete amino-acid data (Table 2) were available for ten
participants due to blood extraction problems, but it should
be noted that the same amino-acid mixture (made by the
same manufacturer) was successfully used in three previous
studies (Cools et al. 2008; Robinson et al. 2009; Robinson
and Sahakian 2009). A repeated-measures ANOVA revealed
a significant two-way drink × time interaction for the critical
TRP/ΣLNAA ratio (treatment × time: F1,29=59, P<0.001).
Simple effects analysis revealed that the significant drink ×
time interaction was due to a 92% decrease in the TRP/
ΣLNAA ratio between T0 and T1 following ATD (significant
effect of time: F1,29=44.7, P<0.001) and a 64% increase in
the TRP/ΣLNAA ratio between T0 and T1 following BAL
(F1,29=18.5, P<0.001).
A similar pattern was seen in the TRP levels on their
own (treatment × time: F1,29=56, P<0.001; significant
effect of time under ATD: F1,29=6.9, P=0.013 and BAL:
F1,29=61, P<0.000).
Mood state
Incomplete VAS scales were available for the first visit of
four subjects (one per group) and for the second visit of two
subjects (one in group 1, one in group 4).
Visit 1
There were no treatment by time (F1,33=0.046, P=0.83),
time by MIP (F1,33=0.13, P=0.73) or treatment by time by
MIP interactions (F1,33=0.50, P=0.48) between T0 and T1
on the Sad VAS subscale. The same absence of an effect
was seen on the happy VAS (no effect of treatment × time,
F1,33=0.68, P=0.42; time × MIP, F1,33=1.6, P=0.22; or
treatment × time × MIP interaction F1,33=0.51, P=0.48).
This indicates that the drink itself did not change subjects'
mood and that this did not differ between groups.
BAL ATD
T1 T2 T1 T2
TRP (nmol/ml) 34 (3.3) 108 (10) 34 (3.2) 10 (9.8)
TRP/ΣLNAA 0.11 (0.01) 0.18 (0.02) 0.12 (0.01) 0.01 (0.02)
Table 2 Biochemical measures
Values represent mean (standard
error of the mean)
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before and after the MIP on the sad VAS (F1,34=9.7, P=
0.004) and although there was no time by MIP (F1,34=2.2,
P=0.15) interaction or time by MIP by treatment interac-
tion (F1,34=0.076, P=0.79), when stratified by group, there
was a significant increase in sad ratings in the negative
(main effect of time; F1,34=9.9, P=0.003) but not neutral
mood group (no effect of time; F1,34=1.44, P=0.24). There
was also an effect of time (F1,34=5.3, P=0.027) and a non-
significant trend towards a time by mood interaction on the
happy VAS (F1,33=3.4, P=0.074) which was again, when
stratified by group, driven by a significant reduction in
happy ratings (main effect of time; F1,33=8.2, P=0.007) in
the negative but not neutral MIP (no effect of time; F1,33=
0.11, P=0.74) group. Thus, the negative MIP increased sad
and decreased happy ratings, whereas the neutral MIP had
no effect on either rating. Thus, although there was no
significant main effect, there was a non-significant trend in
the ‘happy’ ratings, and the simple effects were significant
in both happy and ‘sad’ ratings. As such, we argue that—
consistent with previous studies utilising the same tech-
nique (Robinson 2009; Robinson et al. 2009; Robinson and
Sahakian 2009)—the MIP was successful. The alternative
assumption (that the MIP was unsuccessful) cannot account
for the significant findings on the second visit. The lack of
a main effect may be due to reduced statistical power
resulting from a non-optimal sample size.
Visit 2
There was a significant interaction between time, treatment
and MIP between T0 and T1 on the sad VAS (F1,32=8.0, P=
0.008). This was driven by a significant lowering of mood
in the subjects in group 2 (who underwent both negative
MIP and ATD on the first visit: main effect of time F1,32=
14, P=0.001) but no change in the moods of groups 1 (no
effect of time F1,32=0.077, P=0.78), 3 (no effect of time
F1,32=0.11, P=0.74) or 4 (no effect of time F1,32=1.3, P=
0.25). There was no such interaction on the happy VAS (no
time × treatment × mood interaction: F1,32=0.034, P=
0.85). Thus, ATD evoked negative mood but only in those
subjects who received both negative MIP and ATD on their
first visit (Figs. 1 and 2).
There was also an interaction between time, treatment
and MIP before (T1) and after (T2) the neutral MIP on the
sad VAS (F1,32=5.6, P=0.024). This was due to a
significant reduction in sad ratings following the MIP in
group 2 (main effect of time F1,32=9.8, P=0.004) but no
change in the moods of groups 1 (no effect of time F1,32=
1.6, P=0.22), 3 (no effect of time F1,32=0.37, P=0.55) or 4
(no effect of time F1,32=0.6, P=0.46). There was no such
interaction on the happy VAS (no time × treatment × mood
interaction: F1,32,<0.000, P=0.98). Thus, the neutral MIP
actually served to neutralise the negative mood state
induced by ATD in group 2.
It should be noted that the effect of interest is only
revealed when time is included as a within subjects factor.
There is no significant difference between the sad ratings of
each group at each time point (Table 3). In other words,
there is a significant within- but not between-subjects
change in mood state. This indicates that although a
combination of ATD and mood induction on the first visit
caused a significant change in mood state on a second visit,
this change nevertheless remains within the boundaries of
‘normal’ sad mood ratings.
Fig. 1 Mean difference in the self-report visual analogue scale ‘How
sad are you?’ between T0 and T1 in subjects undergoing ATD. ATD-
induced significant negative mood on visit 2 of those subjects who
received ATD and negative MIP during visit 1 (*P=0.001, NS not
significant)
Fig. 2 Mean difference in the self-report visual analogue scale ‘How
sad are you?’ between T0 and T1 in subjects undergoing BAL. No
changes in mood were seen (NS not significant)
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Tryptophan depletion had no effect upon the mood state of
healthy females on their first visit. However, those who
received negative mood induction following tryptophan
depletion during their first visit experienced a significant
lowering of mood following tryptophan depletion on their
second visit. This effect was not seen in those who
experienced a neutral mood induction and tryptophan
depletion on their first visit or in those who received a
balanced placebo and negative mood induction on their first
visit. This finding therefore provides preliminary experi-
mental data to support the associative hypothesis of
recurrence in depression (Robinson and Sahakian 2008b)
and may therefore explain the discrepancies between the
effects of tryptophan depletion in never- and recovered-
depressed individuals (Booij et al. 2002).
The first important finding, therefore, is that there was
no significant change in mood between T0 and T1 on the
first visit of all four groups. This supports the hypothesis
that tryptophan depletion does not, in itself, cause negative
mood. Although this is inconsistent with early reports
(Young et al. 1986, 1985), more recent studies have failed
to replicate these findings (Booij et al. 2003, 2002), and it is
now thought that any link between 5-HT and mood is likely
to be indirect (Robinson and Sahakian 2009; Ruhe et al.
2007). Moreover, the present data demonstrate that ATD
does not necessarily induce negative mood in healthy
females, despite the suggestion that female gender might be
a risk factor for mood response to ATD (Booij et al. 2002).
Thus, this finding supports the hypothesis that ATD does not
induce negative mood state in healthy individuals who have
never suffered from (and are not predisposed to) depression.
The observation that tryptophan depletion did induce
negative mood on the second visit of those who received
both negative mood and ATD on their first visit then
supports the associative hypothesis of recurrence in
depression (Robinson and Sahakian 2008b). Negative
mood and reduced serotonin frequently co-occur in depres-
sion (APA 2000; Owens and Nemeroff 1994), and ATD
provokes significant negative mood in subjects who have
previously suffered from depression (Booij et al. 2002).
The present findings therefore suggest that ATD may
provoke negative mood in (at least some) recovered
depressed individuals because both negative mood and
reduced serotonin co-occurred during their first episode of
depression.
An important question, therefore, is why previous co-
occurrence of negative mood and low serotonin would
c a u s eA T Dt ob e c o m el i n k e dw i t hn e g a t i v em o o d .A
number of theories which are relevant to this phenomenon
have been highlighted (Robinson and Sahakian 2008b).
The most important of these is associative learning theory,
which describes how two events (in this case, negative
mood and reduced serotonin) can become linked by
occurring at the same time (Dickinson 1981). Future
occurrence of one event then re-evokes the other. Such
learning is thought to be underpinned at the neural level
by Hebbian learning (Paulsen and Sejnowski 2000)i n
which ‘cells that fire together, wire together’.I fb o t ht h e
negative mood and reduced serotonin states evoke
dissociable patterns of neural activity, then these patterns
of neural activity may ‘wire together’ when they co-occur
during an episode of depression (or, indeed, in the
artificial situation in the present study). In particular,
mood states are associated with activity in prefrontal
cortical regions (Garrett and Maddock 2006; Habel et al.
2005; Mayberg et al. 1999;M i t c h e l la n dP h i l l i p s2007;
Taylor Tavares et al. 2008), whereas serotonin influences a
diverse range of cortical and subcortical regions (Cools et
al. 2005;H a r m e r2008;R o i s e re ta l .2007;v a nd e rV e e ne t
al. 2007). Thus, the neurons responsible for the prefrontal
activations associated with negative mood may wire
together with the distinct cortico-subcortical pattern
Group T0 T1 T2
Visit 1
1( N=10) 1.32 (0.71) 1.52 (0.62) 2.06 (0.77)
2( N=9) 0.41 (0.82) 0.94 (0.70) 3.43 (0.91)
3( N=9) 1.53 (0.72) 2.57 (0.62) 3.2 (0.80)
4( N=9) 2.67 (0.71) 2.86 (0.62) 4.29 (0.77)
ANOVA F3,33=1.5, P=0.24 F3,34=0.6, P=0.62 F3,35=0.83, P=0.49
Visit 2
1( N=9) 2.21 (0.74) 2.03 (0.74) 2.66 (0.76)
2( N=8) 0.64 (0.87) 2.9 (0.87) 1.27 (0.89)
3( N=10) 2.96 (0.76) 2.93 (0.77) 3.6 (0.79)
4( N=9) 2.42 (0.74) 1.68 (0.74) 2.06 (0.76)
ANOVA F3,33=1.7, P=0.19 F3,32=1.1, P=0.36 F3,32=1.09, P=0.37
Table 3 Visual analogue ratings
Values represent the visual ana-
logue response to the question
‘How sad are you?’ (cm).
ANOVAs reveal all four groups
to be matched at all time points
Psychopharmacology (2009) 205:227–235 231associated with the reduced serotonin state. This is
redolent of the ‘as-if body’ loop outlined by Damasio
(2000), which postulates that the neural substrates associated
with moods can be independently evoked in the absence of
the somatic changes, which may have originally triggered
the state.
It should be noted that the restriction of this finding to
group 2 indicates that the negative mood state is specifically
associated with the reduced 5-HT state. The absence of the
effect in group 4 indicates that negative mood cannot be
associated with a more general state such as altered amino-
acid levels or discomfort caused by the drink and/or the
long waiting period. In other words, this effect is not driven
by a general state-dependent recall of mood. The reduced
5-HT may therefore provoke increased activation in
specific brain regions (e.g. the striatum Roiser et al.
2007), which may then became associated with the neural
substrates specific to the negative mood state (e.g. regions
of the PFC (Gray et al. 2002; Robinson and Sahakian 2009)).
However, this associative hypothesis is clearly speculative,
and the next step will be to use functional neuroimaging
to examine the neural substrates underlying these prelim-
inary behavioural observations.
This study may also have important implications for our
understanding of relapse in depression. Following a first
episode, subsequent episodes become increasingly likely
(Kendler et al. 2001), and these episodes become increas-
ingly debilitating (Bouhuys and Sam 2000; Fossati et al.
2004; Nandrino et al. 2004; Nandrino et al. 2002; Sher et
al. 2004; Thase et al. 1995) and increasingly easy to trigger
(Lewinsohn et al. 1999). The concept of ‘kindling’ has been
proposed to explain this pattern (Kendler et al. 2001; Post
and Weiss 1998; Segal et al. 1996). In particular, it has been
suggested that permanent changes might occur during a
first episode of depression, which may make subsequent
episodes more likely. The present data highlight the
possibility that a permanent neural association between
reduced serotonin and negative mood, formed during an
episode of depression, may underlie this kindling effect.
Such an association may mean that subsequent fluctuations
in serotonin levels are more likely to trigger depressed mood
and hence instigate a ‘downwards spiral’ into depression.
Such associations could also be partially responsible for the
cognitive impairment which can appear in remission in
recovered depressed individuals (Paradiso et al. 1997).
These findings therefore highlight the importance of
treating not only the initial symptoms of depression but also
any underlying kindling. Specifically, it may be important
to attempt to break these proposed associations after an
episode of depression has been successfully treated.
Associative learning theory suggests that new associations
are formed over the top of old associations rather than old
associations being ‘un-learned’ (Bouton 2002). Thus, one
potential method of treating associations might be to
attempt to associate reduced serotonin with a positive mood
state in recovered depressed individuals. The observation
that the neutral mood induction improved the ATD induced
negative mood in the present study indicates that this may
be possible. Recovered depressed individuals could there-
fore be tryptophan-depleted and then subjected to positive
MIP (Robinson et al. 2009; Robinson and Sahakian 2008a;
Robinson and Sahakian 2009;R o i s e re ta l .2008)o r
behavioural therapy to elevate mood. If the associative
hypothesis is correct, then an association may form between
the low serotonin state and the positive mood state. As
such, future fluctuations in 5-HT level should evoke
positive rather than negative mood and thereby act as a
buffer against the onset of depression. Nevertheless, this
hypothesis is clearly speculative and requires further
research.
It should be noted that whilst this hypothesis explains a
number of previously observed discrepancies, it does not
cover all eventualities. For instance, ATD has actually been
shown to induce negative mood in healthy individuals who
are at risk of depression (Booij et al. 2003; Booij et al.
2002; Neumeister et al. 2002; Ruhe et al. 2007). As such
individuals have never suffered from an episode of
depression the proposed hypothesis cannot explain their
responses. It could be argued that their susceptibility to
depression is provoked by the pre-existence of the proposed
5-HT and mood associations or that their susceptibility
means that they are likely to have experienced sub-clinical
episodes of negative mood and reduced serotonin, but these
arguments are clearly speculative. Similarly, it should be
noted that depression is a multi-faceted disorder and that
not all sufferers experience reduced serotonin. Prior
exposure to SSRIs has been shown to be a predictor of
mood response following ATD (Booij et al. 2002), so it is
plausible that ATD-induced negative mood is only found
in subjects whose depression was associated with reduced
5-HT, but this is also clearly speculative. It should therefore
be emphasised that the proposed hypothesis is only really
applicable to individuals who have experienced an episode
of depression and who experienced reduced 5-HT during
that episode.
As a further caveat, it should be noted that self report is
an imperfect method of measuring mood state because it
can be heavily reliant upon demand characteristics (Orne
1969). This is particularly likely to be an issue with self-
reported mood following mood induction as the desired
mood state is likely to be fairly obvious to the volunteer.
However, it should be noted that the effect of interest in the
present findings was on the second visit prior to the MIP.
Thus, at T1 on the second visit, the experiences of all
groups were closely matched. An alternative demand
characteristic may be that those who experienced negative
232 Psychopharmacology (2009) 205:227–235MIP on the first visit would expect a negative MIP on the
second visit. They may therefore report anticipatory
negative mood just prior to the MIP. However, if this were
the case, then self-reported negative mood would also be
expected in the BAL group who experienced negative MIP
on their first visit. The restriction of the finding to the one
group suggests that the effect is indeed specific to those
who experienced both negative MIP and ATD on the first
visit. It should also be noted that one-way ANOVAs
revealed no significant differences between the ratings of
each group at each time point (see Table 3). This means that
none of the groups had abnormally low or high baseline
mood ratings. As such, the ratings stayed within normal
mood state, and significant effects were driven by signif-
icant within-subject changes in mood state rather than
between-subject differences in mood state. As a further
caveat, the sample size is fairly small, and so these data
should be considered preliminary until they are replicated
in a larger sample of subjects. In fact, the reduced statistical
power associated with this sample size may underlie the
lack of an interaction between MIP and time on the state
ratings on the first visit. Nevertheless, the fact that the
findings support a previously proposed hypothesis is
promising.
Conclusion
In summary, these data provide preliminary support for the
associative hypothesis of recurrence in depression. Reduced
serotonin can evoke negative mood in healthy individuals
but only in those who have previously experienced
concurrent negative mood and reduced serotonin. It is
hypothesised that this is because Hebbian associations form
between the neural substrates of mood and 5-HT during
their co-occurrence. As both reduced serotonin and nega-
tive mood are seen in depression, this may also explain why
serotonin reduction can reliably induce negative mood in
subjects who have recovered from depression but has no
effect upon the moods of healthy individuals. These
associations may therefore underlie, at least in part, the
kindling effect in which an episode of depression makes
subsequent episodes increasingly likely. As depression is a
costly and growing problem, future research should therefore
examine the neural basis of, and the possibility of breaking,
these putative associations, thereby reducing recurrence in
depression. The next step, however, is to replicate these
preliminary findings in a larger sample of subjects.
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